SNCA and Parkinson disease: It was found that, in this PD animal model, myrcene (pre-treatment 30 min prior to rotenone injection) could increase autophagic flux and α-synuclein clearance, and then reduce microglia and astrocyte neurotoxic activation markers (GFAP and Iba1 overexpression) along with pro-inflammatory mediator release and ROS/RNS production.